tbuckley/cabot-search huggingface dataset:
GALVANIC STIMULATION OF MUSCLE FOLLOWING PERIPHERAL NERVE SECTION
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American Journal of Psychiatry, Hanover, NH
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The immunology of exercise. A brief review
Authors: H. B. Simon
Journal: JAMA (1984)

Many athletes believe that habitual exercise protects them against infection. This article reviews ten studies of the effects of exercise on various host-defense factors. Exercise produced a transient granulocytosis and lymphocytosis, and in some studies, lymphocyte function was reported to have been enhanced. Serum immunoglobulin and complement levels were not significantly altered in the small number of subjects studied. Two recent studies showed that exercise produced an increase in circulating endogenous pyrogen in man. Since it now appears that endogenous pyrogen is identical to interleukin-1, a product of mononuclear cells that enhances lymphocyte function, it may play a role in host defense. Further studies will be needed before it can be concluded that exercise effects the host response to infection in any clinically meaningful way. (<i>JAMA</i>1984;252:2735-2738)
Endangered environment: another view
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Successful Aging
Authors: G E Vaillant, K Mukamal
Journal: American Journal of Psychiatry (2001)

OBJECTIVE: Until now, prospective studies of aging have begun with 50–60-year-olds, not adolescents. Premature death, childhood variables, and alcohol abuse have been often ignored, as has successful aging. METHOD: The authors reviewed the existing literature on health in late life in order to highlight that, increasingly, successful aging is not an oxymoron. The present study followed two cohorts of adolescent boys (237 college students and 332 core-city youth) for 60 years or until death. Complete physical examinations were obtained every 5 years and psychosocial data every 2 years. Predictor variables assessed before age 50 included six variables reflecting uncontrollable factors: parental social class, family cohesion, major depression, ancestral longevity, childhood temperament, and physical health at age 50 and seven variables reflecting (at least some) personal control: alcohol abuse, smoking, marital stability, exercise, body mass index, coping mechanisms, and education. The six outcome variables chosen to assess successful aging at age 70–80 included four objectively assessed variables (physical health, death and disability before age 80, social supports, and mental health) and two self-rated variables (instrumental activities of daily living and life enjoyment). RESULTS: Multivariate analysis suggested that “good” and “bad” aging from age 70–80 could be predicted by variables assessed before age 50. More hopeful still, if the seven variables under some personal control were controlled, depression was the only uncontrollable predictor variable that affected the quality of subjective and objective aging. CONCLUSIONS: One may have greater personal control over one’s biopsychosocial health after retirement than previously recognized.
Tracking MRSA
Authors: Joan Stephenson
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transcriptome and colocalisation analysis of CCR9+ gut-homing T cells and other immune cells identifies important genes and biological pathways potentiating primary sclerosing cholangitis risk
Authors: Elizabeth Goode, Nikolaos Panousis, Laura Fachal, Loukas Moutsianas, Ben Bai, Rebecca McIntyre, Tim Raine, Simon Rushbrook, Carl Anderson
Journal: Journal of Hepatology (2020)
The teaching nursing home: a golden annex to the ivory tower
Authors: D. Riesenberg
Journal: JAMA (1987)

In a recent issue ofThe Journal, Schneider and colleagues<sup>1</sup>detail a remarkable increase, during the 1980s, in the number of teaching nursing homes. Additionally, they examine the reasons for this proliferation and speculate on future developments. I find their report encouraging, having not long ago participated in the planning and placement of a nursing home within the walls of a teaching hospital. At the time of that endeavor, I was astonished by the passion with which some educators and many trainees argued against it. Their reservations fell into two categories: (1) doubts about the feasibility of conducting high-quality research in the nursing home setting and (2) the perception that caring for nursing home residents contributes little to the educational process. Schneider et al<sup>1</sup>report that the majority of teaching nursing homes today have active research programs, examining dementia, infectious diseases, and other geriatric issues. Scientific investigation is
The Fifth Annual Report of the Indiana State Board of Medical Registration and Examination for the Year Ending Dec. 31, 1902.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification
Authors: Cora Schäfer, Alexander Heiss, Anke Schwarz, Ralf Westenfeld, Markus Ketteler, Jürgen Floege, Werner Müller-Esterl, Thorsten Schinke, Willi Jahnen-Dechent
Journal: Journal of Clinical Investigation (2003)

Ectopic calcification is a frequent complication of many degenerative diseases. Here we identify the serum protein α2–Heremans-Schmid glycoprotein (Ahsg, also known as fetuin-A) as an important inhibitor of ectopic calcification acting on the systemic level. Ahsg-deficient mice are phenotypically normal, but develop severe calcification of various organs on a mineral and vitamin D–rich diet and on a normal diet when the deficiency is combined with a DBA/2 genetic background. This phenotype is not associated with apparent changes in calcium and phosphate homeostasis, but with a decreased inhibitory activity of the Ahsg-deficient extracellular fluid on mineral formation. The same underlying principle may contribute to many calcifying disorders including calciphylaxis, a syndrome of severe systemic calcification in patients with chronic renal failure. Taken together, our data demonstrate a critical role of Ahsg as an inhibitor of unwanted mineralization and provide a novel therapeutic concept to prevent ectopic calcification accompanying various diseases.
Unintentional Parsimony
Authors: Daniel Kooyman
Journal: JAMA (1976)

<h3>To the Editor.—</h3> In a recent letter (235:1688, 1976), Dr Lemon has achieved a most parsimonious turn of phrase. In his paragraph numbered 3, he refers to "both indigent and foreign observers of the British Medical Service." I'm quite sure that many of the indigenous observers are indeed indigent, and it may well be that if the British system is explored in the United States, many of us foreign observers will be, too. But meanwhile, let's maintain precision of terminology wherever possible.
Public Health Doctors' Conference
Journal: BMJ (1964)

three had grand mal attacks.More recently L. A. Swanson and T. Okada' reported the death of a 38-year-old man from cardiovascular collapse after withdrawal of mepro- bamate, of which he had previously taken up to 10 g. daily.The symptoms of the syndromes of abstinence from barbiturates or meprobamate have much in common with each other and with alcoholic delirium tremens.An initial period of up to 12 hours without symptoms after withdrawal of the drug may mislead the unwary clinician.Thereafter anxiety, insomnia, sweating, vomiting, and tremor develop, followed in severe cases by confusion, fever, hallucinations, epileptic convulsions, and hypotensive heart failure.The convulsions may fail to respond to normal doses of anticonvulsants.I. C. Wilson8 described a patient with status epilepticus after withdrawal of meprobamate and benactyzine, in whom fits were stopped only by restoration of the previous medication, other anti-epileptic measures having failed.Haizlip and
Lectures on the Diagnosis and Surgical Treatment of Abdominal Tumours
Authors: T. S. Wells
Journal: BMJ (1878)

Patient-Inctisiox-Adhesions-Opening and Emptying of Cyst-its Remoml-Treatmen4 qf Pedicie-C'asure of Wound-Dressing ana After-Treatment.AT the end of the last!lecture, we had a supposed patient upon the table, in the position iji which we usually operate at the present day.I should say that some operators still prefer the old position, in which the patient is placed at the foot of the bed, in something like the position for lithotoms or sitting half reclining on the table, the legs widly separated.me operators fix -,the legs in a kind of splint.Wan--and Hegw operate in 'this way, fixing the -patient on a table, lying on -her lck, the legs -separated, verymuch i as if lithotomy were to be6-performed on'the male.The operator'sits'betweenr the legs of the-patient, and operates.sitting.I have seen Nan doing this.The reason he gives is that he is a long time operating.English operators, he says, operate too fast.He takes from one to two or three hours.It is extremely fatiguing for the surgeon to stand all 'that time, and therefore he prefers the sitting position.There are still operators in this country who prefer this position.It was always adopted by Mr. Baker Brown,, and in my first three cases I followed the old practice, but I very soon gave it up.'I found it extremely inconvenient to sit or stand between the legs of the patient.It was difficult to get to-the bottbm of the pelvis, difficult to tie bleeding vessels, difficult to arrange for the escape of fluid without letting it flow into the peritoneal cavity; and
Abstract 852: Determining the roles of ERO1-alpha and ERO1-beta in progression of multiple myeloma and drug resistance
Authors: Weichih Chen, Lori Hazlehurst
Journal: Cancer Research (2019)

Abstract Multiple myeloma (MM) is a hematological malignancy characterized by dysregulated growth and accumulation of monoclonal plasma cells within the bone marrow. It is a treatable but incurable disease. Despite improvement in progression-free and overall survival of MM patients nearly all MM patients will relapse and become resistant to current treatments. Therefore, to find an effective therapeutic target that is applicable to MM, our laboratory analyzed a retrospective study, patients with relapsed MM who had received bortezomib therapy were enrolled in phase 2 and phase 3 clinical trial. Patients who had higher ERO1-alpha expression demonstrated significant poorer outcomes as compared to patients with lower ERO1-alpha expression. Moreover, patients with relapsed myeloma had higher expression of ERO1-alpha protein levels compared to newly diagnosed MM patients, suggesting that ERO1-alpha correlated with disease progress and poor survival of MM patients. Disulfide bond formation is critical for the folding, stability and function of newly synthesized secretory and membrane proteins in endoplasmic reticulum (ER). Endoplasmic reticulum oxidoreductase 1 (ERO1) is an essential component in this process. ERO1-alpha and ERO1-beta are two flavoprotein isomers that have been identified in mammalian cells. ERO1-alpha is widely expressed and up-regulated during oxidative stress and ERO1-beta is only expressed in select tissue and induced by unfold protein response (UPR). We found that knockdown of ERO1-alpha MM cells caused cell growth inhibition and decreased colony formation and lambda secretion. Moreover, overexpression of ERO1-alpha enhanced cell growth. Additionally, reducing the expression of ERO1-alpha resulted in upregulated ERO1-beta by transcriptional and translational levels. Reducing the expression of ERO1-beta in MM cells increased cell growth and induced resistance to current treatments, including the proteasome inhibitor (bortezomib), alkylating agent (melphalan), corticosteroids (dexamethasome) and histone deacetylase inhibitor (panobinostat). We found reducing the expression of ERO1-beta resulted in decreased expression of glucocorticoid receptor (GR). Taken together, our data indicate that ERO1 -alpha and -beta are not functionally redundant as increased alpha expression correlates with MM progression while increased beta expression correlates with increased sensitivity to chemotherapeutic agents. Future studies are aimed at delineation of mechanism underlying the divergent phenotypes that result from reducing ERO1- alpha or -beta in MM cells. Citation Format: Weichih Chen, Lori Hazlehurst. Determining the roles of ERO1-alpha and ERO1-beta in progression of multiple myeloma and drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 852.
P08.48 Combined alterations in MAPK pathway genes, CDKN2A/B and ATRX characterize anaplastic pilocytic astrocytoma
Authors: A. Kratz, F. Sahm, D. Schrimpf, D. T. Jones, D. E. Reuss, J. Schittenhelm, D. Gramatzki, J. Felsberg, A. von Deimling, D. Capper
Journal: Neuro-Oncology (2016)

approximately 15 months following standard of care therapy.However, 10 % survival at 5 years was observed in a randomized phase III study.At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3-4 month prolongation of progression-free survival (PFS) without improving overall survival (OS).A 45-year-old female who underwent surgery for left fronto-temporal WHO grade II astrocytoma associated with epilepsy in 2005, 125I seed implantation at disease progression in 2009 and seed explantation 9 months later, was diagnosed with MGMT methylated GBM on the occasion of partial tumor resection in 2010 followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) chemotherapy, which was stopped after 4 months due to resection of a left temporal tumor cyst and recurrent cyst within 1 month.TMZ treatment causing prolonged thrombocytopenia was discontinued after 1 additional cycle.Immediately after this cycle, the patient experienced left median cerebral artery stroke resulting in right hemianopia, Broca's aphasia and severe hemiparesis of the right side.Three months later, BEV 10 mg/kg i.v.q14d was initiated, shortly interrupted for abdominal herniotomy in 2012, and continued for 3 years.Since 2014, concurrent low molecular weight heparin was given because of right lower limb deep venous thrombosis suspicion.Whereas GBM progression had not been detected for 2 years during anti-VEGF therapy, methionine PET MRI 6 months after BEV discontinuation revealed left temporal tumor recurrence.Rechallenge with BEV was initiated and the patient remained in stable clinical and radiographical condition for 10 months until now.This case highlights the utility of sequential BEV treatment in a patient being at high risk to develop chemotherapy-induced myelotoxicity.Long-term survival (> 3 years after diagnosis) in GBM has been attributed to patient-derived rather than tumor-derived factors.To our knowledge, this is the first description of effective long-term monotherapy with BEV for GBM and ongoing therapeutic response to single-agent BEV rechallenge in a patient with recurrent secondary GBM.
Chronobiology of cardiac sudden death in men
Authors: S. W. Rabkin
Journal: JAMA (1980)

Daily variation in occurrence of sudden cardiac death was examined in 3,983 men observed since 1948. For men without previous clinical evidence of ischemic heart disease, an excess proportion of sudden cardiac deaths occurred on Mondays. For men with previous clinical evidence of ischemic heart disease, sudden cardiac death occurred more uniformly throughout the week. By comparison there was no significant daily variation in cancer mortality or in day of occurrence of myocardial infarction. Thus, for men without clinically manifest heart disease, the warning "beware on Monday" should stimulate further investigation. (<i>JAMA</i>244:1357-1358, 1980)
Prospective, randomized controlled trial of interferon-α in children with chronic hepatitis B
Authors: M Ruiz-Moreno
Journal: Hepatology (1991)

Thirty-six children with chronic hepatitis B were entered into a randomized controlled trial of recombinant human interferon-α All patients had hepatitis B virus DNA and increased levels of aminotransferases in serum for at least 1 yr. Twelve children received 10 MU of interferon-α 2b/m2 body surface area three times a week (group I); 12 children received 5 MU/m2 under the same conditions (group II); and 12 children served as controls (group III). During 6 mo of therapy, 12 of 24 (50%) treated patients (7 from group I, 58%, and 5 from group II, 42%) and 2 of 12 (17%) controls lost hepatitis B virus DNA from serum and subsequently remained negative. Comparison of the rate of response in group I vs. controls showed a statistically significant difference (p < 0.05). Eleven of 12 (92%) treated patients who cleared hepatitis B virus DNA from serum lost HBeAg, seroconverted to anti-HBe and had improvement in liver histological findings with loss of hepatitis B virus DNA from liver. In 10, serum ALT levels became normal. Interferon-α was well tolerated and all children finished therapy. These findings indicate that a 6-mo course of interferon-α is effective in inducing a serological, biochemical and histological remission of disease in approximately 50% of children with chronic hepatitis B. (HEPATOLOGY 1991;13:1035–1039.)
Erysipelothrix Septicaemia
Authors: R. H. Townshend, M. H. Yekta, A. E. Jephcott
Journal: BMJ (1973)

Miss Round.2We await the estimations of vitamin D levels to be completed on random samples from children in our survey.Maybe we shall be shown to be wrong, but in view of the marked difference between the heights and weights of our treated children and the control groups and the correlation of vitaniin D levels with serum alkaline phosphatase found in Asians by Dr. O'Riordan and his colleagues3 we doubt it.A full report on the effects of treatment and on alkaline phos- phatase levels will be submitted for publication shortly.-Weare, etc.,-